

Part I: Description of consignment	I.1. Consignor		I.2. IMSOC reference		I.2.a. Local reference	
	Name				I.3. Central Competent Authority	
	Address				I.4. Local Competent Authority	
	Country		ISO Code			
	I.5. Consignee			I.6. Operator conducting assembly operations independently of an establishment		
	Name			Name		
	Address			Address		
	Country			Approval Number		
				Country		
				ISO Code		
I.7. Country of origin			ISO Code		I.9. Country of destination	
					ISO Code	
I.8. Region of origin			Code		I.10. Region of destination	
					Code	
I.11. Place of dispatch			I.12. Place of destination			
Name			Name			
Address			Address			
Approval Number			Approval Number			
Country			Country			
			ISO Code			
I.13. Place of loading			I.14. Date and time of departure			
Name						
Address						
Approval Number						
Country			ISO Code			
I.15. Means of Transport			I.16. Transporter			
Mode	International transport document	Identification	Name			
			Address			
			Approval Number			
			Country			
			ISO Code			
			I.17. Accompanying documents			
			Commercial document reference		Date of issue	
			Country		Place of issue	
I.18. Transport conditions						
Ambient <input type="checkbox"/>		Chilled <input type="checkbox"/>		Frozen <input type="checkbox"/>		
I.19. Container No / Seal No						
I.20. Certified as						
Germinal products <input type="checkbox"/>						
I.21. For transit through a third country <input type="checkbox"/>						
Third country		ISO Code				
Exit point		BCP code				
Entry point		BCP code				
I.22. For transit through Member State(s) <input type="checkbox"/>			I.23. For export <input type="checkbox"/>			
Member State			Third country			
ISO Code			ISO Code			
			Exit point			
			BCP code			
I.25. Journey Log						
I.26. Total number of packages		I.27. Total quantity		I.28. Total gross weight		
I.30. Description of consignment						
Commodity	Species	Identification Number	Quantity	Nature of commodity		
Identification Mark	Package count	Date of collection / production	Plant / Establishment / Centre	Type		

	II. Health information		
Part II: Certification	I, the undersigned official veterinarian, hereby certify that:		
	II.1.	The semen of equine animals described in Part I has been collected, processed and stored, and dispatched from the semen collection centre(1) which	
	II.1.1.	is approved and kept in a register by the competent authority;	
	II.1.2.	complies with requirements as regards responsibilities, operational procedures, facilities and equipment set out in Part 1 of Annex I to Commission Delegated Regulation (EU) 2020/686.	
	II.2.	The semen described in Part I is intended for artificial reproduction and was obtained from donor animals which	
	II.2.1.	have been born and remained since birth in the Union, or have entered the Union in accordance with the requirements for entry into the Union;	
	II.2.2.	come, before entering the semen collection centre, from establishments in a Member State or zone thereof, or from establishments under official control by the competent authority in a third country or territory, or a zone thereof	
	II.2.2.1.	in which surra (<i>Trypanosoma evansi</i>) has not been reported during the period of the preceding 30 days prior to collection of the semen, and	
	(2)	○ either	[surra has not been reported in the establishment during the period of the preceding 2 years prior to collection of the semen;]
	(2)	○ or	[surra has been reported in the establishment during the period of the preceding 2 years prior to collection of the semen and following the last outbreak the establishment has remained under movement restrictions
	(2)	○ either	[until the remaining animals in the establishment have been subjected to a test for surra with one of the diagnostic methods provided for in Part 3 of Annex I to Commission Delegated Regulation (EU) 2020/688, carried out, with negative results, on samples taken at least 6 months after the last infected animal has been removed from the establishment;]
	(2)	○ or	[for at least 30 days from the date of cleaning and disinfection after the last animal of listed species on the establishment was either killed and destroyed or slaughtered.]
	II.2.2.2.	in which dourine has not been reported during the period of the preceding 6 months prior to collection of the semen, and	
	(2)	○ either	[dourine has not been reported in the establishment during the period of the preceding 2 years prior to collection of the semen;]
	(2)	○ or	[dourine has been reported in the establishment during the period of the preceding 2 years prior to collection of the semen and following the last outbreak, the establishment has remained under movement restrictions
(2)	○ either	[until the remaining equine animals in the establishment, except castrated male equine animals, have been subjected to a test for dourine with the diagnostic method provided for in Part 8 of Annex I to Delegated Regulation (EU) 2020/688, carried out, with negative results, on samples taken at least 6 months after the infected animals have been killed and destroyed or slaughtered, or the infected entire male equine animals have been castrated;]	
(2)	○ or	[for at least 30 days after the last equine animal on the establishment was either killed and destroyed or slaughtered, and the premises were cleaned and disinfected;]	
II.2.2.3.	in which equine infectious anaemia has not been reported during the period of the preceding 90 days prior to collection of the semen, and		
(2)	○ either	[equine infectious anaemia has not been reported on the establishment during the period of the preceding 12 months prior to collection of the semen;]	

Part II: Certification	II. Health information			
	(2)	○ or	[equine infectious anaemia has been reported on the establishment during the period of the preceding 12 months prior to collection of the semen and following the last outbreak the establishment has remained under movement restrictions	
	(2)	○ either	[until the remaining equine animals in the establishment have been subjected to a test for equine infectious anaemia with the diagnostic method provided for in Part 9 of Annex I to Delegated Regulation (EU) 2020/688, carried out, with negative results, on samples taken on two occasions with a minimum interval of 3 months after the infected animals have been killed and destroyed or slaughtered and the establishment was cleaned and disinfected;]	
	(2)	○ or	[for at least 30 days after the last equine animal on the establishment was either killed and destroyed or slaughtered, and the premises were cleaned and disinfected;]	
	II.2.2.4.		in which during the period of 30 days prior to the date of collection of the semen no equine animal has shown signs of infection with equine arteritis virus and of contagious equine metritis (<i>Taylorella equigenitalis</i>);	
	II.2.3.		did not show symptoms or clinical signs of transmissible animal diseases on the day of their admission to a semen collection centre and on the day of collection of the semen;	
	II.2.4.		are identified as provided for in Article 58(1), 59(1) or 62(1) of Commission Delegated Regulation (EU) 2019/2035;	
	II.2.5.		for a period of at least 30 days prior to the date of first collection of the semen and during the collection period	
	II.2.5.1.		were kept on establishments not situated in a restricted zone established due to the occurrence of African horse sickness, infection with <i>Burkholderia mallei</i> (glanders) or of an emerging disease relevant for equine animals;	
	II.2.5.2.		were kept on a single establishment where Venezuelan equine encephalomyelitis, dourine, surra (<i>Trypanosoma evansi</i>), equine infectious anaemia, infection with equine arteritis virus, contagious equine metritis (<i>Taylorella equigenitalis</i>), infection with rabies virus and anthrax have not been reported;	
	II.2.5.3.		were not in contact with animals from establishments situated in a restricted zone due to the occurrence of diseases referred to in point II.2.5.1. or from establishments which do not meet the conditions referred to in point II.2.5.2.;	
	II.2.6.		were not used for natural breeding during a period of at least 30 days prior to the date of first semen collection and between the dates of the first sample referred to in points II.2.7.1., II.2.7.2. and/or II.2.7.3. and until the end of the collection period;	
	II.2.7.		have been subjected to the following tests, referred to in point 1(a) of Chapter I of Part 4 of Annex II to Delegated Regulation (EU) 2020/686, as follows:	
	II.2.7.1.		for infection with equine infectious anaemia (EIA), an agar-gel immunodiffusion test (AGID or Coggins test) or an enzyme-linked immunosorbent assay (ELISA) with a negative result;	
	II.2.7.2.		for infection with equine arteritis virus (EVA),	
(2)	<input type="checkbox"/> either	[II.2.7.2.1. a serum neutralisation test with a negative result at a serum dilution of one in four;]		
(2)	<input type="checkbox"/> and/or	[II.2.7.2.2. a virus isolation test, polymerase chain reaction (PCR) or real-time PCR with a negative result on an aliquot of the entire semen of the donor stallion;]		
II.2.7.3.		for contagious equine metritis (<i>Taylorella equigenitalis</i>) (CEM), an agent identification test carried out on three specimens (swabs) taken from the donor stallion on two occasions with an interval of not less than 7 days at least from the penile sheath (prepuce), the urethra and the fossa glandis;		

Part II: Certification	II. Health information		
		<p>The samples were in no case taken earlier than 7 days (systemic treatment) or 21 days (local treatment) after antimicrobial treatment of the donor stallion and were placed in transport medium with activated charcoal, such as Amies medium, before dispatch to the laboratory where they were subjected with a negative result to a test for:</p>	
	(2)	<input type="checkbox"/> either	[II.2.7.3.1. the isolation of <i>Taylorella equigenitalis</i> after cultivation under microaerophilic conditions for a period of at least 7 days, set up within the 24 hour period after taking the specimens from the donor animal, or the 48 hour period where the specimens are kept cool during transport;]
	(2)	<input type="checkbox"/> and/or	[II.2.7.3.2. the detection of genome of <i>Taylorella equigenitalis</i> by PCR or real-time PCR, carried out within the 48 hour period after taking the specimens from the donor animal;]
	II.2.8.		were subjected with the results specified in point II.2.7. in each case to at least one of the following testing programmes detailed respectively in points 1(b)(i), (ii) and (iii) of Chapter I of Part 4 of Annex II to Delegated Regulation (EU) 2020/686:
	(3)	<input type="checkbox"/>	[II.2.8.1. The donor stallion was continuously resident at the semen collection centre for a period of at least 30 days prior to the date of the first collection and during the period of collection of the semen described in Part I, and no equine animals in the semen collection centre came during that time into direct contact with equine animals of lower health status than the donor stallion. The tests described in point II.2.7. were carried out on samples taken(4) from the donor stallion at least once a year at the beginning of the breeding season or prior to the first collection of semen intended for movement to another Member State as fresh, chilled or frozen semen and not less than 14 days following the date of the commencement of the residence period of at least 30 days prior to the first semen collection.]
	(3)	<input type="checkbox"/>	[II.2.8.2. The donor stallion was resident on the semen collection centre for a period of at least 30 days prior to the date of the first collection and during the period of collection of the semen described in Part I, but left the semen collection centre under the responsibility of the centre veterinarian for a continuous period of less than 14 days during the collection period, or other equine animals in the semen collection centre came into direct contact with equine animals of a lower health status. The tests described in point II.2.7. were carried out on samples taken(4) from the donor stallion at least once a year at the beginning of the breeding season or prior to the date of the first collection of semen intended for movement to another Member State as fresh, chilled or frozen semen and not less than 14 days following the date of the commencement of the residence period of at least 30 days prior to the first semen collection, and during the period of collection of the semen intended for movement to another Member State as fresh, chilled or frozen semen the donor stallion was subjected to the tests described in point II.2.7., as follows:
		(a)	for equine infectious anaemia, one of the tests described in point II.2.7.1. was last carried out on a sample of blood taken(4) not more than 90 days prior to the collection of the semen described in Part I;
		(b)	for infection with equine arteritis virus, one of the tests described
	(2)	<input type="checkbox"/>	[in point II.2.7.2. was last carried out on a sample taken(4) not more than 30 days prior to the date of the collection of the semen described in Part I;]

Part II: Certification	II. Health information			
		(2)	○ or	[in point II.2.7.2.2., in case the non-shedder state of a donor stallion seropositive for infection with equine arteritis virus is confirmed, was carried out on an aliquot of the entire semen of the donor stallion taken(4) not more than 6 months prior to the date of the collection of the semen described in Part I and a blood sample taken(4) from the donor stallion during the 6 months period reacted with a positive result in a serum neutralisation test for infection with equine arteritis virus at a serum dilution of more than one in four;]
			(c)	for contagious equine metritis, the test described in point II.2.7.3. was last carried out on three specimens (swabs) taken(4) not more than 60 days prior to the date of the collection of semen described in Part I
		(2)	○ either	[on two occasions;]
		(2)	○ or	[on a single occasion and subjected to a PCR or real-time PCR.]]
		(3)	<input type="checkbox"/>	II.2.8.3. The donor stallion does not meet the conditions set out in points 1(b)(i) and (ii) of Chapter I of Part 4 of Annex II to Delegated Regulation (EU) 2020/686 and the semen is collected for movement to another Member State as frozen semen. The tests described in points II.2.7.1, II.2.7.2 and II.2.7.3 were carried out on samples taken(4) from the donor stallion at least once a year at the beginning of the breeding season, and the tests described in points II.2.7.1 and II.2.7.3. were carried out on samples taken(4) from the donor stallion during the storage period of the semen of a minimum period of 30 days from the date of the collection of the semen and before the semen is removed from the semen collection centre, not less than 14 days and not more than 90 days after the collection of the semen described in Part I, and
		(2)	○ either	[the tests for infection with equine arteritis virus described in point II.2.7.2. were carried out on samples taken(4) during the storage period of the semen of a minimum period of 30 days from the date of the collection of the semen and before the semen is removed from the semen collection centre or used, not less than 14 days and not more than 90 days after the date of the collection of the semen described in Part I.]
		(2)	○ or	[the non-shedder state of a donor stallion seropositive for infection with equine arteritis virus was confirmed by virus isolation test, PCR or real-time PCR carried out with a negative result on samples of an aliquot of the entire semen of the donor stallion taken(4) twice a year at an interval of at least 4 months and the donor stallion has reacted with a positive result at a serum dilution of at least one in four in a serum neutralisation test for infection with equine arteritis virus.]
		II.2.9.		underwent the testing provided for in point II.2.8. on samples taken on the following dates:

Part II: Certification	II. Health information								
	Identificat ion of semen	Test programm e	Start date(4)	Date of sampling for health tests(4)					
				Donor residence	Semen collection	EIA II.2.7.1.	EVA II.2.7.2. Blood sample	Semen sample	CEM II.2.7.3. 1. sample
	—	—	—	—	—	—	—	—	—
	—	—	—	—	—	—	—	—	—
	—	—	—	—	—	—	—	—	—
	—	—	—	—	—	—	—	—	—
	—	—	—	—	—	—	—	—	—
	—	—	—	—	—	—	—	—	—
	—	—	—	—	—	—	—	—	—

Part II: Certification	II. Health information		
	<p>II.3. The semen described in Part I</p> <p>II.3.1. has been collected, processed and stored in accordance with animal health requirements set out in points 1 and 2 of Part 1 of Annex III to Delegated Regulation (EU) 2020/686;</p> <p>II.3.2. are placed in straws or other packages on which the mark is applied in accordance with requirements provided for in Article 10 of Delegated Regulation (EU) 2020/686 and that mark is indicated in Box I.30;</p> <p>II.3.3. is transported in a container which:</p> <p>II.3.3.1. was sealed and numbered prior to the dispatch from the semen collection centre under responsibility of the centre veterinarian, or by an official veterinarian, and the seal bears the number as indicated in Box I.19;</p> <p>II.3.3.2. has been cleaned and either disinfected or sterilised before use, or is single-use container;</p> <p>(2)(5) <input type="checkbox"/> [II.3.3.3. has been filled in with the cryogenic agent which not have been previously used for other products.]</p> <p>(2)(6) <input type="checkbox"/> The semen is preserved by the addition of antibiotics as follows:</p> <p>II.4.</p> <p>II.4.1. The following antibiotic or mixture of antibiotics has been added to the semen after final dilution, or is contained in the used semen diluents, to reach the indicated concentration per ml of semen:</p> <p>(2) <input type="radio"/> either [a mixture of gentamicin (250 µg), tylosin (50 µg) and lincomycin-spectinomycin (150/300 µg);]</p> <p>(2) <input type="radio"/> or [a mixture of lincomycin-spectinomycin (150/300 µg), penicillin (500 IU) and streptomycin (500 µg);]</p> <p>(2) <input type="radio"/> or [a mixture of amikacin (75 µg) and divekacin (25 µg);]</p> <p>(2) <input type="radio"/> or [an antibiotic or a mixture of antibiotics(7) _____, with a bactericidal activity at least equivalent to one of the following mixtures:</p> <ul style="list-style-type: none"> - gentamicin (250 µg), tylosin (50 µg) and lincomycin-spectinomycin (150/300 µg); - lincomycin-spectinomycin (150/300 µg), penicillin (500 IU) and streptomycin (500 µg); - amikacin (75 µg) and divekacin (25 µg).] <p>II.4.2. Immediately after the addition of the antibiotics, and before any possible freezing, the diluted semen was kept at a temperature of at least 5°C for a period of not less than 45 minutes, or under a time-temperature regime with a documented equivalent bactericidal activity.]</p>		

Part II: Certification	II. Health information																					
	<p>Notes</p> <p>This animal health certificate shall be completed according to the notes for the completion of certificates provided for in Chapter 2 of Annex I to Commission Implementing Regulation (EU) 2020/2235.</p> <p>Part I:</p> <p>Box reference I.11: “Place of dispatch”: Indicate the unique approval number and the name and address of the semen collection centre of dispatch of the consignment of semen.</p> <p>Box reference I.12: “Place of destination”: Indicate the address and unique registration or approval number of the establishment of destination of the consignment of semen.</p> <p>Box reference I.19: Seal number shall be indicated.</p> <p>Box reference I.26: Total number of packages shall correspond to the number of containers.</p> <p>Box reference I.30: “Type”: semen.</p> <p>“Identification number”: Indicate identification number of each donor animal.</p> <p>“Identification mark”: Indicate mark on the straw or other packages where semen of the consignment is placed.</p> <p>“Date of collection/production”: Indicate the date on which semen of the consignment was collected.</p> <p>“Approval or registration number of plant/establishment/centre”: Indicate the unique approval number of the semen collection centre where the semen was collected.</p> <p>“Quantity”: Indicate number of straws or other packages with the same mark.</p> <p>Part II:</p> <p>Guidance for the completion of the table in point II.2.9.</p> <p>Abbreviations:</p> <table data-bbox="271 1321 1212 1747"> <tr><td>EIA-1</td><td>Equine infectious anaemia (EIA) testing first occasion</td></tr> <tr><td>EIA-2</td><td>EIA testing second occasion</td></tr> <tr><td>EVA-B1</td><td>Equine arteritis virus (EVA) testing on blood sample first occasion</td></tr> <tr><td>EVA-B2</td><td>EVA testing on blood sample second occasion</td></tr> <tr><td>EVA-S1</td><td>EVA testing on semen sample first occasion</td></tr> <tr><td>EVA-S2</td><td>EVA testing on semen sample second occasion</td></tr> <tr><td>CEM-11</td><td>Contagious equine metritis (CEM) testing first occasion first sample</td></tr> <tr><td>CEM-12</td><td>CEM testing first occasion second sample taken 7 days after CEM-11</td></tr> <tr><td>CEM-21</td><td>CEM testing second occasion first sample</td></tr> <tr><td>CEM-22</td><td>CEM testing second occasion second sample taken 7 days after CEM-21</td></tr> </table> <p>Instructions:</p> <p>For each semen identified in column A in correspondence with Box I.30, the test programme (points II.2.8.1., II.2.8.2. and/or II.2.8.3.) shall be specified in column B, and columns C and D shall be completed with the dates required.</p> <p>The dates when samples were taken for laboratory testing prior to the first collection of the semen described in Part I as required in points II.2.8.1., II.2.8.2. and II.2.8.3., shall be entered in the upper line of columns 5 to 9 of the table, this being the boxes marked with EIA-1, EVA-B1 or EVA-S1 and CEM-11 and CEM-12 in the example below.</p>			EIA-1	Equine infectious anaemia (EIA) testing first occasion	EIA-2	EIA testing second occasion	EVA-B1	Equine arteritis virus (EVA) testing on blood sample first occasion	EVA-B2	EVA testing on blood sample second occasion	EVA-S1	EVA testing on semen sample first occasion	EVA-S2	EVA testing on semen sample second occasion	CEM-11	Contagious equine metritis (CEM) testing first occasion first sample	CEM-12	CEM testing first occasion second sample taken 7 days after CEM-11	CEM-21	CEM testing second occasion first sample	CEM-22
EIA-1	Equine infectious anaemia (EIA) testing first occasion																					
EIA-2	EIA testing second occasion																					
EVA-B1	Equine arteritis virus (EVA) testing on blood sample first occasion																					
EVA-B2	EVA testing on blood sample second occasion																					
EVA-S1	EVA testing on semen sample first occasion																					
EVA-S2	EVA testing on semen sample second occasion																					
CEM-11	Contagious equine metritis (CEM) testing first occasion first sample																					
CEM-12	CEM testing first occasion second sample taken 7 days after CEM-11																					
CEM-21	CEM testing second occasion first sample																					
CEM-22	CEM testing second occasion second sample taken 7 days after CEM-21																					

Part II: Certification	II. Health information								
	<p>The dates when samples were taken for repeat laboratory testing as required in accordance with point II.2.8.2. or II.2.8.3. shall be entered in the lower line of columns 5 to 9 in table, this being the boxes EIA-2, EVA-B2 or EVA-S2 and CEM-21 and CEM-22 in the example below.</p>								
	Identificat ion of semen		Test programm e	Start date	Date of sampling for health tests				
				Donor residence	Semen collection	EIA II.2.7.1.	EVA II.2.7.2.	CEM II.2.7.3.	
						Blood sample	Semen sample	1. sample	2. sample
	A	B	C	D	EIA-1	EVA-B1	EVA-S1	CEM-11	CEM-12
					EIA-2	EVA-B2	EVA-S2	CEM-21	CEM-22
	(1)	Only semen collection centres approved by the competent authority and included in the register referred to in Article 101(1)(b) of Regulation (EU) 2016/429 and Article 7 of Delegated Regulation (EU) 2020/686.							
	(2)	Delete if not applicable.							
	(3)	Cross out the programmes that do not apply to the consignment.							
(4)	Insert date in table in point II.2.9. (follow Guidance in Part II of the Notes).								
(5)	Applicable for frozen semen.								
(6)	Mandatory attestation in case antibiotics were added.								
(7)	Insert the name(s) of the antibiotic(s) added and its(their) concentration or the commercial name of the semen diluent containing antibiotics.								
Certifying Officer/Official veterinarian									
Name (in capital letters)				Qualification and title					
Date of signature				Signature					
Stamp									